{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:35:50Z","timestamp":1789011350491,"version":"build-2803163510"},"reference-count":30,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Takeda","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C37712\/A21282"],"award-info":[{"award-number":["C37712\/A21282"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C7852\/A25447"],"award-info":[{"award-number":["C7852\/A25447"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb Company","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,3,24]]},"published-print":{"date-parts":[[2022,6]]},"abstract":"\n Introduction<\/jats:title>\n Multiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population.<\/jats:p>\n Over the last 10 years, patient outcomes have improved. However, this is less apparent in older, less fit patients, who are ineligible for stem cell transplant. Research is required in this patient group, taking into account frailty and aiming to improve: treatment tolerability, clinical outcomes and quality of life.<\/jats:p>\n <\/jats:sec>\n \n Methods and analysis<\/jats:title>\n Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma is a national, phase III, multicentre, randomised controlled trial comparing standard (reactive) and frailty-adjusted (adaptive) induction therapy delivery with ixazomib, lenalidomide and dexamethasone (IRD), and to compare maintenance lenalidomide to lenalidomide+ixazomib, in patients with newly diagnosed multiple myeloma not suitable for stem cell transplant. Overall, 740 participants will be registered into the trial to allow 720 and 478 to be randomised at induction and maintenance, respectively.<\/jats:p>\n All participants will receive IRD induction with the dosing strategy randomised (1:1) at trial entry. Patients randomised to the standard, reactive arm will commence at the full dose followed by toxicity dependent reactive modifications. Patients randomised to the adaptive arm will commence at a dose level determined by their International Myeloma Working Group frailty score. Following 12 cycles of induction treatment, participants alive and progression free will undergo a second (double-blind) randomisation on a 1:1 basis to maintenance treatment with lenalidomide+placebo versus lenalidomide+ixazomib until disease progression or intolerance.<\/jats:p>\n <\/jats:sec>\n \n Ethics and dissemination<\/jats:title>\n Ethical approval has been obtained from the North East\u2014Tyne & Wear South Research Ethics Committee (19\/NE\/0125) and capacity and capability confirmed by local research and development departments for each participating centre prior to opening to recruitment. Participants are required to provide written informed consent prior to trial registration. Trial results will be disseminated by conference presentations and peer-reviewed publications.<\/jats:p>\n <\/jats:sec>\n \n Trial registration number<\/jats:title>\n \n ISRCTN17973108<\/jats:ext-link>\n ,\n NCT03720041<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-056147","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:27:58Z","timestamp":1654169278000},"page":"e056147","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":37,"title":["F<\/i>\n railty-adjusted therapy\n i<\/i>\n n\n T<\/i>\n ransplant\n N<\/i>\n on-\n E<\/i>\n ligible patient\n s<\/i>\n with newly diagno\n s<\/i>\n ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"isrctn17973108","registry":"10.18810\/isrctn"},{"clinical-trial-number":"nct03720041","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"isrctn49407852","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn49407852","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn68454111","registry":"10.18810\/isrctn"},{"clinical-trial-number":"isrctn68454111","registry":"10.18810\/isrctn"},{"clinical-trial-number":"nct00689936","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01564537","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1810-409X","authenticated-orcid":false,"given":"Amy Beth","family":"Coulson","sequence":"first","affiliation":[{"name":"Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-1199","authenticated-orcid":false,"given":"Kara-Louise","family":"Royle","sequence":"additional","affiliation":[{"name":"Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Pawlyn","sequence":"additional","affiliation":[{"name":"Cancer Research UK London Research Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Cairns","sequence":"additional","affiliation":[{"name":"Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hockaday","sequence":"additional","affiliation":[{"name":"Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bird","sequence":"additional","affiliation":[{"name":"Department of Haematology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Bowcock","sequence":"additional","affiliation":[{"name":"Department of Haematology, Kings College Hospital NHS Foundation Trust, Princess Royal Hospital, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Institute of Cancer Research, London, UK"},{"name":"The Department of Haemato-oncology, Royal Marsden Hospital NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"de Tute","sequence":"additional","affiliation":[{"name":"Haematology Malignancy Diagnostic Service (HMDS), St James's University Hospital, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Rabin","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Boyd","sequence":"additional","affiliation":[{"name":"The Department of Haemato-oncology, Royal Marsden Hospital NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Jones","sequence":"additional","affiliation":[{"name":"King's College Hospital, London, UK"},{"name":"Brighton and Sussex Medical School, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Parrish","sequence":"additional","affiliation":[{"name":"Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Gardner","sequence":"additional","affiliation":[{"name":"Department of Haematology and Stem Cell Transplantation, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Meads","sequence":"additional","affiliation":[{"name":"Academic Unit of Health Economics, University of Leeds, Leeds Institute of Health Sciences, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryony","family":"Dawkins","sequence":"additional","affiliation":[{"name":"Academic Unit of Health Economics, University of Leeds, Leeds Institute of Health Sciences, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Olivier","sequence":"additional","affiliation":[{"name":"Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowena","family":"Henderson","sequence":"additional","affiliation":[{"name":"Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Best","sequence":"additional","affiliation":[{"name":"Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Owen","sequence":"additional","affiliation":[{"name":"Haematology Malignancy Diagnostic Service (HMDS), St James's University Hospital, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Jenner","sequence":"additional","affiliation":[{"name":"Southampton General Hospital, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvan","family":"Kishore","sequence":"additional","affiliation":[{"name":"Department of Haematology and Stem Cell Transplantation, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Drayson","sequence":"additional","affiliation":[{"name":"Institute of Immunology and Immunotherapy, Department of Haematology, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Haematology, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[{"name":"Leeds Institute of Clinical Trials Research, University of Leeds Clinical Trials Research Unit, Leeds, West Yorkshire, UK"},{"name":"Leeds Cancer Centre, St James's University Hospital, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"2025121602510561000_12.6.e056147.1","unstructured":"Cancer Research UK . Myeloma Incidence Statistics [online], 2015. Available: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma\/incidence"},{"key":"2025121602510561000_12.6.e056147.2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3211"},{"key":"2025121602510561000_12.6.e056147.3","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"key":"2025121602510561000_12.6.e056147.4","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1016\/S2352-3026(19)30167-X","article-title":"Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"6","author":"Jackson","year":"2019","journal-title":"Lancet Haematol"},{"key":"2025121602510561000_12.6.e056147.5","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.189.189","article-title":"Quadruplet vs sequential triplet induction therapy approaches to maximise response for newly diagnosed, transplant eligible, myeloma patients","volume":"126","author":"Pawlyn","year":"2015","journal-title":"Blood"},{"key":"2025121602510561000_12.6.e056147.6","doi-asserted-by":"crossref","first-page":"e1003454","DOI":"10.1371\/journal.pmed.1003454","article-title":"Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (myeloma XI+): interim analysis of an open-label randomised controlled trial","volume":"18","author":"Jackson","year":"2021","journal-title":"PLoS Med"},{"key":"2025121602510561000_12.6.e056147.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-548826"},{"key":"2025121602510561000_12.6.e056147.8","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2147\/OTT.S49187","article-title":"An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma","volume":"7","author":"Offidani","year":"2014","journal-title":"Onco Targets Ther"},{"key":"2025121602510561000_12.6.e056147.9","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.71"},{"key":"2025121602510561000_12.6.e056147.10","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12542"},{"key":"2025121602510561000_12.6.e056147.11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71125-8"},{"key":"2025121602510561000_12.6.e056147.12","doi-asserted-by":"crossref","unstructured":"Moreau P , Masszi T , Grzasko N . Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival (pfs) for patients (PTS) with relapsed and\/or refractory multiple myeloma (RRMM): the phase 3 Tourmaline-MM1 study (NCT01564537). Am Soc Hematology 2015.","DOI":"10.1182\/blood.V126.23.727.727"},{"key":"2025121602510561000_12.6.e056147.13","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/S2152-2650(20)30955-1","article-title":"MM-347: Ixazomib plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for newly diagnosed multiple myeloma (NDMM) patients not eligible for autologous stem cell transplant: the double-blind, placebo-controlled, phase 3 TOURMALINE-MM2 trial","volume":"20","author":"Facon","year":"2020","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"2025121602510561000_12.6.e056147.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"2025121602510561000_12.6.e056147.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1963.03060120024016"},{"key":"2025121602510561000_12.6.e056147.16","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/9.3_Part_1.179"},{"key":"2025121602510561000_12.6.e056147.17","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2025121602510561000_12.6.e056147.18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.120121"},{"key":"2025121602510561000_12.6.e056147.19","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood.V128.22.1143.1143","article-title":"Lenalidomide is a highly effective maintenance therapy in myeloma patients of all ages; results of the phase III myeloma XI study","volume":"128","author":"Jackson","year":"2016","journal-title":"Blood"},{"key":"2025121602510561000_12.6.e056147.20","unstructured":"Jackson G , Davies FE , Pawlyn C . Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the myeloma XI trial. Blood 2017;130."},{"key":"2025121602510561000_12.6.e056147.21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.82.82","article-title":"Long-Term Ixazomib maintenance is Tolerable and improves depth of response following Ixazomib-Lenalidomide-Dexamethasone induction in patients (PTS) with previously untreated multiple myeloma (Mm): phase 2 study results","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"key":"2025121602510561000_12.6.e056147.22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02060"},{"key":"2025121602510561000_12.6.e056147.23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2025121602510561000_12.6.e056147.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586"},{"key":"2025121602510561000_12.6.e056147.25","unstructured":"The International Myeloma Working Group (IMWG) . Updated criteria for the diagnosis of multiple myeloma. The Lancet 2014;15."},{"key":"2025121602510561000_12.6.e056147.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"2025121602510561000_12.6.e056147.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"2025121602510561000_12.6.e056147.28","unstructured":"Pawlyn C , Davies FE , Cairns D . Continuous treatment with lenalidomide improves outcomes in newly diagnosed myeloma patients not eligible for autologous stem cell transplant: results of the myeloma XI trial. ASH 2017."},{"key":"2025121602510561000_12.6.e056147.29","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16945","article-title":"Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from myeloma XI, a multicentre, open-label, randomised, phase III trial","volume":"192","author":"Jackson","year":"2021","journal-title":"Br J Haematol"},{"key":"2025121602510561000_12.6.e056147.30","doi-asserted-by":"publisher","DOI":"10.2307\/2530245"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-056147","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:51:17Z","timestamp":1765882277000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-056147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,2]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1136\/bmjopen-2021-056147"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-056147","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}